JP2002529408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002529408A5 JP2002529408A5 JP2000580616A JP2000580616A JP2002529408A5 JP 2002529408 A5 JP2002529408 A5 JP 2002529408A5 JP 2000580616 A JP2000580616 A JP 2000580616A JP 2000580616 A JP2000580616 A JP 2000580616A JP 2002529408 A5 JP2002529408 A5 JP 2002529408A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- pharmaceutical composition
- propionyl
- carnitine
- anticancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002253 acid Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT1998/000318 WO2000027386A1 (en) | 1998-11-11 | 1998-11-11 | Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation |
| IT1998RM000701A IT1302858B1 (it) | 1998-11-11 | 1998-11-11 | Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento avente attivita' antitumorale. |
| IT9800318 | 1998-11-11 | ||
| IT98A000701 | 1998-11-11 | ||
| PCT/IT1999/000357 WO2000027387A1 (en) | 1998-11-11 | 1999-11-09 | Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002529408A JP2002529408A (ja) | 2002-09-10 |
| JP2002529408A5 true JP2002529408A5 (enExample) | 2006-12-28 |
Family
ID=26330215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000580616A Pending JP2002529408A (ja) | 1998-11-11 | 1999-11-09 | アポトーシスを誘導することができる薬剤の調製のためのプロピオニルｌ−カルニチンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1128823A1 (enExample) |
| JP (1) | JP2002529408A (enExample) |
| KR (1) | KR100694004B1 (enExample) |
| AU (1) | AU1294600A (enExample) |
| CA (1) | CA2350071A1 (enExample) |
| WO (1) | WO2000027387A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101006207B1 (ko) * | 2008-09-25 | 2011-01-07 | 김형호 | 잡음차단수단을 갖는 헤드셋 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254314B (it) * | 1992-03-27 | 1995-09-14 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari. |
| EP0681839A3 (en) * | 1994-05-12 | 1997-11-12 | Hirohiko Kuratsune | A pharmaceutical preparation comprising an acylcarnitine |
| US5786326A (en) * | 1995-02-03 | 1998-07-28 | Horwitz; Lawrence D. | Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation |
| IT1276253B1 (it) * | 1995-12-15 | 1997-10-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi |
| DK0793962T3 (da) * | 1996-03-04 | 2000-05-22 | Sigma Tau Ind Farmaceuti | Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans |
| IT1283951B1 (it) * | 1996-03-15 | 1998-05-07 | Mendes Srl | Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di |
-
1999
- 1999-11-09 KR KR1020017005575A patent/KR100694004B1/ko not_active Expired - Fee Related
- 1999-11-09 CA CA002350071A patent/CA2350071A1/en not_active Abandoned
- 1999-11-09 AU AU12946/00A patent/AU1294600A/en not_active Abandoned
- 1999-11-09 WO PCT/IT1999/000357 patent/WO2000027387A1/en not_active Ceased
- 1999-11-09 JP JP2000580616A patent/JP2002529408A/ja active Pending
- 1999-11-09 EP EP99956317A patent/EP1128823A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mueller et al. | Interim report of multicenter double-blind, placebo-controlled studies of nifedipine in chronic stable angina | |
| US4871742A (en) | Process and pharmaceutical compositions for the treatment of glaucoma | |
| JP2002521428A5 (enExample) | ||
| JPH027572B2 (enExample) | ||
| JP2013529654A (ja) | レボカルニチン及びドベシレートを含む医薬組成物 | |
| JP2002528502A5 (enExample) | ||
| JP4456267B2 (ja) | 抗アテローム性動脈硬化剤としてのヴィティス・ヴィニフェラ（ｖｉｔｉｓｖｉｎｉｆｅｒａ）抽出物のリン脂質複合体の使用 | |
| TW200908977A (en) | Use of a PAR-1 antagonist for the treatment of atrial fibrillation | |
| JP2008503504A5 (enExample) | ||
| JP2002509164A5 (enExample) | ||
| US5861434A (en) | Compositions containing L-carnitine or an acyl L-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders | |
| AU726822B2 (en) | Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism | |
| US20080021083A1 (en) | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance | |
| CA2505937A1 (en) | Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropaties induced by anticancer agents | |
| JP2002529408A5 (enExample) | ||
| ES2208721T3 (es) | Nuevas asociaciones que comprenden (-)hidroxicitratos y que tienen nuevas actividades terapeuticas. | |
| US6333352B1 (en) | Method of treating benign positional vertigo | |
| JP2769217B2 (ja) | 心臓状態の処置のためのプロパフェノン及びキニジンの持効性組成物 | |
| JPS649288B2 (enExample) | ||
| JP2006523685A5 (enExample) | ||
| JP2006523685A (ja) | 循環器疾患の治療のためのｌ−カルニチンの使用 | |
| KR100725263B1 (ko) | ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 | |
| JP2004532866A5 (enExample) | ||
| RU2336076C2 (ru) | Пероральное лекарственное средство для восполнения дефицита магния в организме | |
| AU2003259261B2 (en) | Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure |